Robin Foa, MD, Sapienza University

home / authors / robin-foa-md-sapienza-university

Articles

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Jorge Cortes, MD, Georgia Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

Jorge Cortes, MD, Georgia Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

Jorge E. Cortes, MD, MD Anderson Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

Jorge Cortes, MD, Georgia Cancer Center;Robin Foa, MD, Sapienza University;Elias Jabbour, MD, MD Anderson Cancer Center;Doug Smith, MD, John Hopkins Medicine

July 8th 2021

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).